Cargando…

Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer

Methylation alterations of specific genes have recently been identified as diagnostic biomarkers for human cancers. Although MEG3 has been proved to be a tumor suppressor in cervical cancer according to our previous study, the diagnostic value of MEG3 methylation in plasma is still unknown. Therefor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jun, Yao, Tingting, Lin, Zhongqiu, Gao, Yali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524906/ https://www.ncbi.nlm.nih.gov/pubmed/28740189 http://dx.doi.org/10.1038/s41598-017-06502-7

Ejemplares similares

Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer
por: Zhang, Jun, et al.
Publicado: (2017)

Hypermethylation of MEG3 promoter correlates with inactivation of MEG3 and poor prognosis in patients with retinoblastoma
por: Gao, Yali, et al.
Publicado: (2017)

Long non-coding RNA MEG3 inhibits cervical cancer cell growth by promoting degradation of P-STAT3 protein via ubiquitination
por: Zhang, Jun, et al.
Publicado: (2019)

DNA Methylation Aberrant in Atherosclerosis
por: Dai, Yao, et al.
Publicado: (2022)

Aberrant DNA methylation in cervical Carcinogenesis
por: Yang, Hui-Juan
Publicado: (2013)

Mechanism associated with aberrant lncRNA MEG3 expression in gestational diabetes mellitus
por: Zhang, Hailing
Publicado: (2019)

The expression of ALDH1 in cervical carcinoma
por: Yao, Tingting, et al.
Publicado: (2011)

Potential applications of MEG3 in cancer diagnosis and prognosis
por: He, Yuqing, et al.
Publicado: (2017)

DNMT1 facilitates growth of breast cancer by inducing MEG3 hyper-methylation
por: Zhu, Xiaotao, et al.
Publicado: (2022)

The long noncoding RNA MEG3 regulates Ras-MAPK pathway through RASA1 in trophoblast and is associated with unexplained recurrent spontaneous abortion
por: Zhang, Jun, et al.
Publicado: (2021)

Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
por: Micevic, Goran, et al.
Publicado: (2017)

TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population
por: Yao, Hongxia, et al.
Publicado: (2017)

Association of the Plasma Long Non-coding RNA MEG3 With Parkinson's Disease
por: Quan, Yi, et al.
Publicado: (2020)

Aberrant Promoter Methylation and Expression of UTF1 during Cervical Carcinogenesis
por: Guenin, Samuel, et al.
Publicado: (2012)

A New Approach to Evaluating Aberrant DNA Methylation Profiles in Hepatocellular Carcinoma as Potential Biomarkers
por: Yang, Yuan, et al.
Publicado: (2017)

Aberrant methylation of dipeptidyl peptidase‑like 6 as a potential prognostic biomarker for lung adenocarcinoma
por: Munkhjargal, Batkhishig, et al.
Publicado: (2023)

Aberrant Methylation of PCDH8 is a Potential Prognostic Biomarker for Patients with Clear Cell Renal Cell Carcinoma
por: Lin, Ying-Li, et al.
Publicado: (2014)

LncRNA MEG3: Potential stock for precision treatment of cardiovascular diseases
por: Li, Zining, et al.
Publicado: (2022)

Maternal blood lead concentrations, DNA methylation of MEG3 DMR regulating the DLK1/MEG3 imprinted domain and early growth in a multiethnic cohort
por: Nye, Monica D., et al.
Publicado: (2016)

Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients
por: Li, Shao-ying, et al.
Publicado: (2014)

Biomarkers for autism spectrum disorder: opportunities for magnetoencephalography (MEG)
por: Roberts, Timothy P. L., et al.
Publicado: (2021)

Potential Use of MEG to Understand Abnormalities in Auditory Function in Clinical Populations
por: Larson, Eric, et al.
Publicado: (2014)

Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
por: Lin, Ying-Li, et al.
Publicado: (2014)

Long non-coding RNA MEG3 suppresses survival, migration, and invasion of cervical cancer
por: Chen, Xiuhui, et al.
Publicado: (2018)

Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas
por: Yokoyama, Seiya, et al.
Publicado: (2016)

Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer
por: Liu, Wentao, et al.
Publicado: (2018)

Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS
por: Schoonhoven, Deborah N, et al.
Publicado: (2018)

Measuring functional connectivity with wearable MEG
por: Boto, Elena, et al.
Publicado: (2021)

MEG3 regulates apoptosis of adipose-derived stem cells
por: Shi, Yao
Publicado: (2020)

Cadmium exposure and MEG3 methylation differences between Whites and African Americans in the NEST Cohort
por: House, John S, et al.
Publicado: (2019)

Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma
por: Nakaoka, Toshiaki, et al.
Publicado: (2017)

Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer
por: Fang, Xingyu, et al.
Publicado: (2020)

LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer
por: Wang, Wei, et al.
Publicado: (2019)

LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis
por: Du, Ying, et al.
Publicado: (2022)

ALDH-1-positive cells exhibited a radioresistant phenotype that was enhanced with hypoxia in cervical cancer
por: Yao, Tingting, et al.
Publicado: (2020)

Temple syndrome in a patient with variably methylated CpGs at the primary MEG3/DLK1:IG-DMR and severely hypomethylated CpGs at the secondary MEG3:TSS-DMR
por: Kagami, Masayo, et al.
Publicado: (2019)

Long non-coding RNA AK001903 regulates tumor progression in cervical cancer
por: Zhong, Guanglei, et al.
Publicado: (2021)

Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer
por: Demircan Tan, Berna, et al.
Publicado: (2020)

Evolution of MEG: A first MEG‐feasible fluxgate magnetometer
por: Koshev, Nikolay, et al.
Publicado: (2021)

Pilot study of plasma creatine riboside as a potential biomarker for cervical cancer
por: Oike, Takahiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_10siom6o23o4pcsimerfp4gqas